TTAC-0001 and Pembrolizumab Combination phase1b Trial in Recurrent Glioblastoma
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 20
Summary
- Conditions
- Recurrent Glioblastoma
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: N/AIntervention Model: Sequential AssignmentIntervention Model Description: This was mTPI design to start with optimal dose and next dose level is selected accroding to DLT occurranceMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03722342
- Collaborators
- Not Provided
- Investigators
- Not Provided
Get Well Soon